Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
orally) improves survival compare to placebo
17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-5-[(diaminomethylidene)amino]pentanamide
Smiles: [Gd+3]
Catania MA
Epub 2019 Jul 24
XL184 (Cabozantinib) cuolin-1 orally) improves survival compare toCabozantinib, also known as XL 184 or BMS 907351, is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several tyrosine receptor kinases. Specifically, cabozantinib appears to have a strong affinity for the hepatocyte growth factor receptor (Met) and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in inhibition of
US$ 225.00
US$ 119.95
US$ 114.97
US$ 149.00
US$ 39.95
US$ 225.00